Background: psoriasis is a chronic, debilitating, autoimmune disease that adversely affects the individual's quality of life; the disease progresses with periods of flare-ups and remission. Psoriasis affects approximately 2% of the global population. Psoriasis can begin at any age, however, the mean age of onset was 15-20 years old and the second peak period was 55-60years of age . Aim of the Work: this study aimed to evaluate the serum level of visfatin in psoriatic patients and its relation to duration and severity of psoriasis. Subjects and Methods: the present study represents a case-control study which was carried out on 20 patients with psoriasis vulgaris and 20 age and sex matched healthy volunteers as the controls. Results: in the present study, serum level of visfatin in patients group was statistically significant higher than serum level of visfatin in the control group. There was a significant positive correlation between visfatin level and PASI score proposing visfatin as a marker of psoriasis severity. Conclusion: Visfatin is one of adipokines that may have a role in the pathogenesis of psoriasis and its severity in addition to its role in the cardiovascular system diseases, which may explain the relation between psoriasis and cardiovascular complications and their severity in the psoriatic patients.